Skip to main content
PharmaResources (Shanghai) Co., Ltd. logo

PharmaResources (Shanghai) Co., Ltd. — Investor Relations & Filings

Ticker · 301230 ISIN · CNE1000065Q9 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 458 across all filing types
Latest filing 2023-07-21 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 301230

About PharmaResources (Shanghai) Co., Ltd.

https://www.pharmaresources.cn

PharmaResources (Shanghai) Co., Ltd. is a comprehensive Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) specializing in small molecule drug discovery and development. The company provides an integrated platform of services including medicinal chemistry, custom synthesis, process research and development, and analytical chemistry. PharmaResources supports global pharmaceutical and biotechnology partners through the entire drug development lifecycle, from initial lead optimization to the commercial-scale manufacturing of advanced intermediates and Active Pharmaceutical Ingredients (APIs). With a focus on technical innovation and quality management, the firm utilizes advanced synthetic methodologies and process engineering to accelerate drug candidates toward clinical trials and market approval.

Recent filings

Filing Released Lang Actions
关于完成工商变更登记并换发营业执照的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the completion of a business registration change and the issuance of a new business license for Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It references prior announcements and details the updated company registration information such as name, legal representative, registered capital, and business scope. The document is short (889 characters) and serves as a formal notification of a corporate registration update rather than a financial report or detailed management information. It does not contain financial data, audit information, or meeting materials. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-07-21 Chinese
公司章程
Governance Information Classification · 100% confidence The document is a detailed company charter or articles of association for Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It includes chapters on general provisions, business scope, shares, shareholders and shareholders' meetings, board of directors, senior management, supervisory board, financial accounting system, profit distribution, audit, notices and announcements, mergers, capital changes, dissolution, and amendments to the articles. The content is legal and governance-related, specifying shareholder rights, board responsibilities, meeting procedures, share issuance and transfer rules, and other corporate governance matters. There is no financial data, earnings information, audit report, or announcement of voting results. The document is not a report of financial performance or a meeting presentation but a governance document outlining the company's internal rules and structure. Therefore, the most appropriate classification is Governance Information (CGR).
2023-07-12 Chinese
2023年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 2023 second extraordinary general meeting of shareholders of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It details the meeting date, voting methods, attendance, voting results, and legal opinions confirming the validity of the meeting and resolutions. The key content is the official voting results of shareholder decisions, including approval of capital changes and amendments to the company charter. There is no detailed financial data, management discussion, or full report content. The document is not a full annual or interim report, nor a proxy solicitation or presentation. It is a formal declaration of voting results from a shareholders meeting, matching the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is under 5,000 characters and it contains substantive voting results, not just a notice of report publication or certification, so it is not RPA or RNS.
2023-07-12 Chinese
2023年半年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2023 semi-annual performance forecast (业绩预告) for the period January 1, 2023 to June 30, 2023. It provides preliminary profit estimates and growth percentages compared to the prior year but explicitly states that the financial data has not been audited and is based on preliminary calculations. It also notes that the final detailed financial data will be disclosed in the 2023 semi-annual report. The document is short (836 characters) and serves as an earnings forecast rather than a full interim or quarterly report containing actual financial statements or substantive financial data. Therefore, it is best classified as an Earnings Release (ER), which covers initial announcements of quarterly or periodical financial results with key highlights only. H1 2023
2023-07-12 Chinese
北京市嘉源律师事务所关于上海泓博智源医药股份有限公司2023年第二次临时股东大会的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, and validity of a specific shareholders' meeting (the 2023 second extraordinary general meeting) of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It details the legal compliance of the meeting's notice, attendance, voting procedures, and results. It does not contain financial statements, earnings data, or management discussion. It is not a report of financial results or an announcement of voting results but a legal opinion on the meeting's procedural legality. Given the nature of the document as a legal opinion letter related to a shareholders' meeting, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory or compliance documents that do not fit other specific categories.
2023-07-12 Chinese
上海泓博智源医药股份有限公司章程修订案
Share Issue/Capital Change Classification · 95% confidence The document is a board meeting announcement regarding the approval of changes to the company's registered capital and amendments to the company's articles of association. It includes specific details about the increase in registered capital and share count, and mentions that the changes require shareholder approval. This is an announcement of a capital change and related corporate governance update, not a full report or financial statement. The document length is short (581 characters), and it is not a report itself but an announcement of proposed changes. Therefore, the most appropriate classification is 'Share Issue/Capital Change' (SHA).
2023-06-26 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.